ENYO Pharma assures Phase Ib Trial in Chronic HBV afflicted Patients

ENYO Pharma SA declared that it is strengthening its leadership team with the appointment of a VP Non-Clinical Development & Product Profiling. ENYO Pharma also confirms that its Phase Ib trial evaluating the safety of EYP001 in chronic HBV infected patients is progressing well in Europe and in the Asia-Pacific region.

Jacky Vonderscher, Chief Executive Officer of ENYO Pharma commented: “We are delighted to welcome an expert in NASH and in Nuclear Receptors who will add important new skills and experience to our Executive Team and help us optimizing all aspects of our development plans. Now that we have demonstrated safety in Healthy Subjects and clear target engagement for our FXR agonist EYP001 in Chronic HBV infected patients, we are planning to start two Phase IIa studies, one in CHBV patients and one in NASH patients, in H2 2018. NASH is a valuable additional opportunity for our lead compound and significantly strengthens our portfolio as FXR agonism has already been validated to play an important role in NASH.”

A phase Ib multicenter, randomized, double-blind, placebo-controlled study in chronic HBV patients was initiated at the end of 2017 to determine the safety and tolerability of daily oral administration of EYP001 over 4 weeks. The study is performed in Poland, Netherlands, Thailand and Australia.